The HPS6 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-mediated gene-disrupted polyclonal population derived from the human SK-HEP-1 cell line, engineered to abrogate expression of the HPS6 gene. This product provides a heterogeneous pool of edited cells, each carrying disruption at the target locus, enabling loss-of-function studies without clonal selection. The polyclonal format preserves the genetic diversity inherent to the edited population, offering a robust model for investigating HPS6-dependent processes.
The SK-HEP-1 cell line originates from a human liver adenocarcinoma, exhibiting functional capacities of hepatocytes, including xenobiotic metabolism, detoxification, and protein synthesis. While maintaining malignant characteristics, these cells retain key hepatic features such as expression of albumin, transferrin, and cytochrome P450 enzymes, making them suitable for studying hepatocyte biology and drug metabolism, as well as liver cancer pathobiology. This background provides a unique platform to examine the role of genes like HPS6 in a hepatic context where lysosome-related organelle function may intersect with metabolic activity.
HPS6 encodes a subunit of the biogenesis of lysosome-related organelles complex-2 (BLOC-2), which cooperates with the adaptor protein complex-3 (AP-3) to direct cargo trafficking to melanosomes, platelet dense granules, and other LROs. Mechanistically, HPS6 functions downstream of transcription factors MITF and SOX10, which regulate melanocyte differentiation, and is required for the proper delivery of enzymes such as TYR, TYRP1, and DCT essential for melanin synthesis. Additionally, HPS6 interacts closely with HPS3 and HPS5 within BLOC-2, and disruption of this complex impairs the biogenesis and maturation of melanosomes and platelet dense granules, leading to deficiencies in pigmentation and platelet cargo loading of serotonin and ADP.
In the SK-HEP-1 liver adenocarcinoma background, HPS6 knockout models Hermansky-Pudlak syndrome type 6, a genetic disorder characterized by oculocutaneous albinism, bleeding diathesis, and often pulmonary fibrosis. Although SK-HEP-1 cells are not of melanocytic or platelet lineage, they express components of the BLOC-2 pathway and machinery for lysosome-related organelle formation, enabling investigation of fundamental LRO biogenesis mechanisms. This model allows researchers to dissect how HPS6 deficiency affects endosomal trafficking and lysosomal function in hepatic cancer cells, potentially uncovering novel links between LRO biology and hepatocarcinogenesis or metabolic dysregulation.
The HPS6 Knockout SK-HEP-1 Polyclonal Cells support a wide range of applications, including the study of lysosome-related organelle biogenesis, drug screening for lysosomal storage or trafficking disorders, and functional dissection of HPS6 in liver cancer cells. Representative assays include genomic DNA sequencing and RT-qPCR for confirming gene disruption, western blotting for protein validation, immunofluorescence microscopy for LAMP1 or melanosomal markers, lysosomal enzyme activity measurements, melanin content quantification, and cell viability assays under lysosomal stress or drug challenge. For additional technical details and support, please contact Ascent Research.
